{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "GBp", "marketState": "CLOSED", "regularMarketChangePercent": -0.85574573, "regularMarketPrice": 405.5, "exchange": "CXE", "shortName": "Oxford Biomedica PLC", "longName": "Oxford Biomedica plc", "exchangeTimezoneName": "Europe/London", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "market": "gb_market", "esgPopulated": false, "regularMarketTime": 1683905369, "earningsTimestamp": 1682424000, "earningsTimestampStart": 1682424000, "earningsTimestampEnd": 1682424000, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.41, "sharesOutstanding": 96460896, "bookValue": 2.126, "fiftyDayAverage": 4.2364063, "fiftyDayAverageChange": 401.26358, "fiftyDayAverageChangePercent": 94.71792, "twoHundredDayAverage": 4.2364063, "twoHundredDayAverageChange": 401.26358, "twoHundredDayAverageChangePercent": 94.71792, "marketCap": 39114895360, "priceToBook": 190.73378, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1681887600000, "priceHint": 2, "regularMarketChange": -3.5, "regularMarketDayHigh": 416.0, "regularMarketDayRange": "400.0 - 416.0", "regularMarketDayLow": 400.0, "regularMarketVolume": 5428, "regularMarketPreviousClose": 409.0, "bid": 404.5, "ask": 407.5, "fullExchangeName": "Cboe UK", "financialCurrency": "GBP", "regularMarketOpen": 408.0, "averageDailyVolume3Month": 7103, "averageDailyVolume10Day": 8595, "fiftyTwoWeekLowChange": 401.525, "fiftyTwoWeekLowChangePercent": 101.01258, "fiftyTwoWeekRange": "3.975 - 416.0", "fiftyTwoWeekHighChange": -10.5, "fiftyTwoWeekHighChangePercent": -0.025240384, "fiftyTwoWeekLow": 3.975, "fiftyTwoWeekHigh": 416.0, "symbol": "OXBL.XC"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Windrush Court", "address2": "Transport Way", "city": "Oxford", "zip": "OX4 6LT", "country": "United Kingdom", "phone": "44 1865 783 000", "website": "https://www.oxb.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological malignancies and tumours; and OXB-401 that is in pre-clinical stage for the treatment of liver indication; as well as OXB-40X, OXB-40Y, and OXB-40Z, which are in pre-clinical stage for liver indication. The company has collaborations with Boehringer Ingelheim, Immatics, Arcellx, Orchard, and Beam Therapeutics; an agreement with Homology Medicines; license and clinical supply agreement with Juno Therapeutics, Inc.; and master services and development agreement with AstraZeneca UK Ltd and Serum Life Sciences Ltd. The company also has a strategic collaboration with Kite Pharma to develop and commercialize CART-ddBCMA, a lead late-stage product candidate. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.", "fullTimeEmployees": 894, "companyOfficers": [{"maxAge": 1, "name": "Mr. Stuart  Paynter", "age": 48, "title": "CFO, Company Sec. & Director", "yearBorn": 1974, "fiscalYear": 2021, "totalPay": {"raw": 755000, "fmt": "755k", "longFmt": "755,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Frank  Mathias", "age": 60, "title": "CEO & Director", "yearBorn": 1962, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Nick  Page", "title": "Chief Operations Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. James  Miskin Ph.D.", "title": "Chief Technical Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Kyriacos  Mitrophanous Ph.D.", "title": "Chief Scientific Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Matthew  Treagus", "title": "Chief Information Officer & Chief of Staff", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Sophia  Bolhassan", "title": "Head of Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Natalie Louise Walter", "title": "Gen. Counsel", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Lisa  James", "title": "Chief People Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Sarah  Macleod", "title": "Head of Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 9, "boardRisk": 5, "compensationRisk": 9, "shareHolderRightsRisk": 1, "overallRisk": 9, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1640908800, "maxAge": 86400}}], "error": null}}